A APM apoia a Campanha Março Borgonha, de conscientização sobre o Mieloma Múltiplo, tipo de câncer desconhecido por grande parte da sociedade médica. Embora a prevalência seja maior em idosos, jovens também podem desenvolver a doença. Durante o mês, divulgaremos informações e entrevistas com especialistas em nossas mídias sociais. Acesse o site da campanha e acompanhe nossos canais!
Frauke Naumann-Winter, Alexander Greb, Peter Borchmann, Julia Bohlius, Andreas Engert, Roland Schnell
Several clinical studies have compared single with tandem (also called double) autologous stem cell transplantation (ASCT) as first-line treatment in patients with symptomatic multiple myeloma (MM), one of the leading indications for ASCT worldwide.
The present Cochrane Review compares tandem autologous stem celltransplantation (TASCT) with single autologous stem celltransplantation (SASCT) as first-line treatmentin patients with symptomatic MM with respectto overall survival (OS), event-free survival (EFS), quality of life (QoL) and treatment- or transplantation-related mortality.
We systematically identified controlled trials published between January 1995 and May 2011 in two bibliographic databases (MEDLINE and CENTRAL) and in clinical trial registries.
One researcher screened references for controlled trials to determine eligibility for the systematic review (SR) according to pre-specified inclusion and exclusion criteria, reflecting characteristics of disease and the interventions. We required a minimal set of details to be reported for observational studies for the studies to be included.
Data collection and analysis
We critically evaluated eligible trials with respect to quality of design and actual performance. One researcher extracted individual trial results, which were checked by another researcher. We recapitulated the results of the individual trials in a standardised way for the SR in order to allow a systematic assessment of potential sources of bias.
Há nove anos, hematologistas e oncologistas se reúnem anualmente em um simpósio educacional organizado por um hospital brasileiro e outro norte-americano. Durante o Board Review 2015, uma pesquisa foi conduzida entre os participantes e avaliou as diferenças na conduta e opções de tratamento para o mieloma múltiplo (MM).
A growing population of long-term survivors of myeloma is now accumulating the ‘late effects’ not only of myeloma itself, but also of several lines of treatment given throughout the course of the disease.
Multiple myeloma (MM) is characterized by the neoplastic proliferation of clonal plasma cells producing a monoclonal immunoglobulin. These clonal plasma cells proliferate in the bone marrow and often result in extensive skeletal destruction with osteolytic lesions, osteopenia, and/or pathologic fractures.
Autores: Elaine Cristina Faria Abrahão Machado, Cínthia Mendes, Lissa Sabino de Matos, Caroline Romanelli Tiburcio Zelenika, Marcel Alex Soares dos Santos, Marcela Baraldi Moreira, Bogdana Victoria Kadunc, Ana Helena Kalies Oliveira